VERAXA Biotech appoints interim CFO
Seeking Alpha ·
VERAXA Biotech ( VRXA ) appointed Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister Carl von Halem currently serves as CFO of Xlife Sciences and played a key role in VERAXA’s public listing. Veraxa Biotech: Post-Merger Valuation Does Not Match The Risk Financial information for Veraxa Biotech AG
DYAX Investor Sentiment
Bullish (Long) 40% · Bearish (Short) 60%
309 participants
Related News
- The Vanguard ETF Warren Buffett Endorsed in 2014 Would Have Turned $5,000 Into $20,465 Today
- This Unstoppable Tech ETF Is Down More Than 20%. Is It Time to Buy the Dip?
- Elon Musk's SpaceX Just Joined the Nasdaq-100. Now What?
- 2 Beaten-Down Stocks That Still Aren't Worth Buying
- 5 Top AI Stocks Investors Own on Robinhood
- Berkshire Hathaway (BRK.A) Is Making An $8.5 Billion Bet On Homes And AI